You are here
Calder Biosciences Inc.
UEI: YZYMDHZG3ZN7
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
Amount: $1,928,617.00Respiratory Syncytial Virus (RSV) infection in the elderly causes great human suffering due to hospitalization and death, and is considered a societal burden similar to that of seasonal influenza. Vac ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
Amount: $299,740.00Respiratory Syncytial VirusRSVinfection in the elderly causes great human suffering due to hospitalization and deathand is considered a societal burden similar to that of seasonal influenzaVaccines fo ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA
Amount: $2,861,512.00An Influenza pandemic remains an acute threat to world health; and stockpiling a universally protective Influenza vaccine provides a strong defense against this potential catastrophe. The hemagglutini ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination
Amount: $599,742.00A Respiratory Syncytial VirusRSVvaccine is not yet availableAvatar is developing a noveldi tyrosine crosslinkedconformationally locked preF subunit immunogenDT preFthatformulated with an adjuvantwill ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health
